HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will Roche Be Among The First To Launch An Approved COVID Self-Test In Germany?

Executive Summary

Roche's new CE-marked nasal-swab antigen test could be a good candidate for approval within Germany's recently liberalized COVID-19 self-test market. 

You may also be interested in...



Diagnostics Saves Roche From Q1 Difficulties

In its first quarter 2021 sales earnings report, Roche highlighted the strength of its diagnostics business as biosimilars cannibalize its pharmaceutical revenues.

COVID-19 Self-Tests Could Hit German Retail Shelves In A Matter Of Weeks

In Germany, a draft reguation circulated to industry associations proposes the sale of COVID-19 antigen tests directly to the public. If the amendment to Germany's medical devices regulations is approved, the onus will be on manufacturers to submit viable tests for approval, with the country's in-vitro testing industry association suggesting that this could be achieved in a matter of weeks. 

Consumer Health Industry Ideally Placed To Lead And Benefit From Climate Fight

Consumer healthcare firms are perfectly placed to lead the charge in fighting climate change while benefitting from the transition to a greener, healthier world. However, taking advantage of the green opportunity means putting environmental, social and governance (ESG) at the center of how OTC companies measure and reward success and treating the health of people and planet as a single, related issue, argues Bayer Consumer Health's sustainability guru Daniella Foster. 

Topics

UsernamePublicRestriction

Register

RS150969

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel